JP2024501537A5 - - Google Patents
Info
- Publication number
- JP2024501537A5 JP2024501537A5 JP2023539966A JP2023539966A JP2024501537A5 JP 2024501537 A5 JP2024501537 A5 JP 2024501537A5 JP 2023539966 A JP2023539966 A JP 2023539966A JP 2023539966 A JP2023539966 A JP 2023539966A JP 2024501537 A5 JP2024501537 A5 JP 2024501537A5
- Authority
- JP
- Japan
- Prior art keywords
- nhr
- compound according
- optionally
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026064884A JP2026120662A (ja) | 2020-12-30 | 2026-04-10 | セレブロンに結合する新規な化合物、及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/PL2020/000099 WO2022146151A1 (en) | 2020-12-30 | 2020-12-30 | Novel compounds which bind to cereblon, and methods of use thereof |
| PLPCT/PL2020/000099 | 2020-12-30 | ||
| PCT/EP2021/087847 WO2022144416A1 (en) | 2020-12-30 | 2021-12-30 | Novel compounds which bind to cereblon, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026064884A Division JP2026120662A (ja) | 2020-12-30 | 2026-04-10 | セレブロンに結合する新規な化合物、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501537A JP2024501537A (ja) | 2024-01-12 |
| JP2024501537A5 true JP2024501537A5 (enExample) | 2025-01-09 |
| JP7853713B2 JP7853713B2 (ja) | 2026-04-30 |
Family
ID=74347684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023539966A Active JP7853713B2 (ja) | 2020-12-30 | 2021-12-30 | セレブロンに結合する新規な化合物、及びその使用方法 |
| JP2026064884A Pending JP2026120662A (ja) | 2020-12-30 | 2026-04-10 | セレブロンに結合する新規な化合物、及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026064884A Pending JP2026120662A (ja) | 2020-12-30 | 2026-04-10 | セレブロンに結合する新規な化合物、及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240307547A1 (enExample) |
| EP (1) | EP4271670A1 (enExample) |
| JP (2) | JP7853713B2 (enExample) |
| KR (1) | KR20230128083A (enExample) |
| CN (1) | CN116917275A (enExample) |
| WO (2) | WO2022146151A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| AU2024344247A1 (en) | 2023-09-19 | 2026-05-07 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025097090A1 (en) * | 2023-11-02 | 2025-05-08 | Neomorph, Inc. | Substituted (piperidin-4-yl)-1,5-naphthyridine and (piperidin-4-yl)quinoline derivatives and uses thereof |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| AU2007290407A1 (en) | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
| HUE035389T2 (en) | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| EP4649963A3 (en) * | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| ES2843973T3 (es) * | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| WO2017197046A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2018064589A1 (en) * | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| JP7258009B2 (ja) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
-
2020
- 2020-12-30 WO PCT/PL2020/000099 patent/WO2022146151A1/en not_active Ceased
-
2021
- 2021-12-30 CN CN202180094397.3A patent/CN116917275A/zh active Pending
- 2021-12-30 WO PCT/EP2021/087847 patent/WO2022144416A1/en not_active Ceased
- 2021-12-30 EP EP21847732.1A patent/EP4271670A1/en active Pending
- 2021-12-30 KR KR1020237026080A patent/KR20230128083A/ko active Pending
- 2021-12-30 JP JP2023539966A patent/JP7853713B2/ja active Active
- 2021-12-30 US US18/259,868 patent/US20240307547A1/en active Pending
-
2026
- 2026-04-10 JP JP2026064884A patent/JP2026120662A/ja active Pending